Neurotech issued a prospectus in September, 2016 where the issue...

Neurotech issued a prospectus in September, 2016 where the issue of patent protection was discussed in some detail. My understanding (without claiming any expertise in the area of patents) from this document is:
1) Four patents have been granted in Malta (numbers 4339, 4340, 4355 and 4356).
2) These patents have been granted without prior art search or examination, so there is a risk that other inventors of similar technology exist with priority. sec 7.2(f)
3) Neurotech is unable to now apply for patents for the same technology in other jurisdictions. sec 7.2(g)

Neurotech's response to this situation is summarised in this (also sec 7.2(g)) statement:


Thank you for (persistently) asking this question. The answer is an important part of the risk equation for investors in Neurotech. Also, anybody looking forward to a fat, juicy takeover might find that the offer price is discounted due to our weak IP position.


Also... I expect a GA from everybody who reads this! I've spent a couple of hours searching patent offices and trawling the Internet to find this information.